Latest Recurring Revenue News

FirstWave has unveiled a strategic shift towards AI-powered compliance management, backed by strong user growth for its Open-AudIT platform and significant cost savings from restructuring.

FlexiRoam Limited reveals a strong financial turnaround with AI-powered innovations driving profitability and margin expansion in the first half of FY26. The company’s strategic partnerships and zero-integration platform position it well in the fast-growing eSIM market.

Jcurve Solutions has reported a robust Q2FY26 with a significant profit turnaround and a confident revenue outlook for FY26, driven by strong sales and recurring revenue growth.

DataWorks has secured a significant contract extension with iGaming Ontario, adding over C$12.5 million to its Centralised Self-Exclusion program services. This move strengthens its recurring revenue and solidifies its RegTech division’s profitability.

Vection Technologies has secured a $2.2 million defence contract for its new FEDRA edge data appliance, marking a significant step in its AI-powered military technology portfolio under a $22.3 million framework agreement.

Aura Consolidated Group and Qoria Limited have announced a merger to create AXQ, a global leader in digital safety and cybersecurity, backed by a US$75 million equity raise and targeting strong growth and innovation.

Aura Consolidated Group Inc. is set to acquire Qoria Limited in a landmark $3 billion merger, creating a global leader in digital safety solutions with a new ASX listing under the ticker AXQ.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Memphasys Limited secures significant repeat orders from Hamad Medical Corporation, marking a pivotal expansion of its Felix™ system across the MENA region.

Big moves came from consumer fintech names as investors quickly re-priced growth, losses, and capital needs. A capital-raise week also split the market: some raisings steadied prices, others triggered fresh selling.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.